Answer
Its licensed uses depend on a tumour carrying a relevant BRAF mutation, so a validated test is needed to identify patients for whom treatment is appropriate.
Sources for this answer
- Mekinist film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
- Spexotras 0.05 mg/ml powder for oral solution — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.